IMS helps customers identify an optimal mix of products in their portfolios and pipelines to advance healthcare and produce the best returns. For example, we work with our customers to determine which therapy classes to enter … which products to develop and license … how to achieve the right marketing mix across the product portfolio … and which acquisitions to consider. In a market driven by innovation, IMS measures the performance of product portfolios, delivers high-impact products, services and solutions, and helps answer mission-critical questions.
At IMS, we help customers assess current and future product potential … determine how to allocate resources across their portfolios to get the best return on investment … and consider which products in the pipeline should be developed to maximize their success.
IMS data and applications have always been at the core of Portfolio Optimization. At IMS, we respond to customers' needs in this arena with services and offerings around Market Opportunity Assessment, Strategic Business Planning, New Business Development, and Market Analysis. And our Portfolio Optimization team continues to define new offerings and channels that better serve our customers' requirements in this critical field.
Our offerings help clients discover unmet market needs, evaluate potential new markets and therapies, assess product uptake, and develop short- and long-term forecasts - by region and therapeutic class. With these solutions, clients are able to:
-
Determine investment levels for new product research.
-
Assess market viability.
-
Determine launch strategies to achieve rapid market penetration by focusing on key competitors.
-
Monitor the uptake of new and existing products from a strategic perspective.
-
Determine the ROI of specific physician-related activities such as Continuing Medical Education and targeted selling efforts.
At the heart of IMS market assessments are powerful data assets that provide business intelligence at every level - from sales volume and market share to prescribing trends by product, company, geography and distribution channel. These include Canadian Drug Store and Hospital Purchases Audit (CDH), Compuscript, Canadian Disease and Therapeutic Index (CDTI), and Canadian Promotion Audit (CPA).
We also provide in-depth reporting and analysis of emerging trends within healthcare. Decision-makers use these reports for strategic planning, policy formulation, business development and ongoing assessment of the Canadian healthcare environment. Five-year market forecasts, updated commentary on federal and provincial healthcare policies - combined with expert insight - are the defining elements of our annual PharmaFocus.
The rate of post-launch product uptake is a key success factor in today's competitive marketplace. IMS AnalogueTM develops penetration curves for product launches, based on market characteristics, product attributes and external factors such as regulatory issues, reimbursement and formulary trends. Strategic planning directors and product marketing executives also benefit from access to IMS Therapy ForecasterTM. Whether the task is a company's annual strategic planning or budgeting exercise, or merger and acquisition analysis, a review of licensing or joint venture opportunities, these 10-year forecasts of 40 therapeutic classes provide a wealth of actionable information.
Obtaining formulary status for products is an essential element of pharmaceutical market success. Our Provincial Reimbursement Advisor (PRA) service is a quarterly report monitoring key reimbursement issues facing the Canadian pharmaceutical industry. Clients receive timely information and analysis of the trends and government policies influencing market access, a critical factor for launch success.
We draw on these and other information assets to design offerings that rise to the challenge of optimizing pharma product portfolios. Sometimes simple questions are the most difficult to answer - and the most important. What products to license? Which therapy classes to enter? Which drugs get the marketing money and which do not? How will a client's current portfolio perform over the next 3-5 years? To get the answers, IMS creates tailored solutions combining the power of our data and applications with our team's expertise.
Whether it's in-depth business intelligence, analysis, or forecasting, IMS offerings provide pharma customers with the facts, interpretations and guidance they need to make the best portfolio-optimization decisions.